Conference: principles, present and futur goals of anti-cancer radiotherapy

• Jacques BALOSSO (Centre François BACLESSE à Caen, France)
• Jacques BALOSSO (Université Joseph Fourier, Grenoble)

Cancer radiotherapy is a locoregional treatment of cancer using physical processes. Its place has continued to be consolidated for more than a century with very rapid technological developments in recent years driven by the evolution of the possibilities of medical imaging and faster and more accurate dose calculations. It has continuously developed in close association with surgery and systemic cancer treatments and its current evolution remains characterized by this therapeutic cooperation aiming to cure cancer. The current objectives are to continue to increase cure rates while reducing toxicities which remain significant in the medium and long term and represent a limiting element of this therapy. Furthermore, in the era of personalization of care, the anatomical and dosimetric adaptation to the tumor which has always existed for radiotherapy must today integrate other dimensions such as the radio sensitivity of tumors, the radio sensitivity of patients, and the objective choice of different technical treatment possibilities. These different aspects from the basic principle of radiotherapy to the objectives for the years to come will be presented in this conference

Innovative radiotherapies (1)

• Rachel Delorme (Univ. Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3, 38000 Grenoble, France)

These lectures will cover an ntroduction to the physical and radiobiological characteristics of the different approaches and technological issues associated with their development. The approach in developing new radiotherapy (RT) approaches is to succeed in increasing the therapeutic window for different types of cancer, either by sparing healthy tissues, or by being more effective on the tumor tissue to be treated, ideally both at the same time. An introduction will be given presenting different developments in modern X-ray RT with successive generations of irradiation techniques improving the conformation of the dose to the tumor and optimized dose delivery for the patient's response. The limits of external RT will be discussed and a broad description of development strategies developed to overcome these limits will be given, in particular to see how we can play on the physical aspects of irradiation to induce a different biological response. We will emphasize the interest of using beams different from photons, such as light ions (H, C) used in hadrontherapy, which have the dual advantage of providing better irradiation ballistics and increased biological efficiency for radioresistant cancers. Other approaches also play on the temporal and spatial aspects of dose delivery, such as “FLASH” radiotherapy using a very high dose rate and “spatial fractionation” using very heterogeneous irradiation with micrometric beams, to induce better tolerance of healthy tissues to irradiation for the same tumor control. Finally, non-localized or metastatic cancers can benefit from combined approaches with the use of a pharmaceutical agent allowing molecular targeting of cancer cells, as is the case with internal radiotherapy or boron neutron capture (BNCT). Finally, we will briefly introduce the questions that these RT raises, whether in terms of understanding the induced radiobiological mechanisms or the technological developments that they require in terms of production, dosimetry or detection, these different aspects being the subject of specific courses in the following.

Radiobiology (for physicists): experimental aspects 1

• Julie Costanzo (ICM Montpellier)

Aspects expérimentaux, méthodologiques, instrumentaux et phénoménologiques de la radiobiologie

Geant4-DNA: Modelling biological damage induced by ionising radiation at the DNA level

• Hoang Tran (LP2iB)

Geant4-DNA is an extension of the Geant4 Monte Carlo toolkit designed for mechanistic studies of cellular radiobiological effects at the DNA scale. It simulates the physical, chemical, and biological stages of ionizing radiation, including electrons, protons, alpha particles, and heavier ions, for various applications. The applications of Geant4-DNA range from predicting radiotherapy outcomes to radiation protection and space applications. These lectures provide an overview of the progress achieved with physical, physicochemical, chemical, and biological geometry models integrated into Geant4-DNA. The latest developments are highlighted, including user-friendly applications such as 'molecularDNA' and 'dsbandrepair', which are based on these models. These applications allow for quantitative predictions of early DNA damage, such as single-strand breaks (SSBs), double-strand breaks (DSBs), and the complexity of clustered lesions across different levels of DNA structure, from the DNA base to the full genome of a human cell. The lectures will present sets of models, functionalities, and user examples in Geant4-DNA. These capabilities allow for the investigation of radiation quality across a range of ionizing radiations, covering a broad spectrum of radiotherapeutic modalities. This spectrum includes high-energy hadron beams, as well as low-energy gamma, beta, or alpha emitters used in brachytherapy sources and radiopharmaceuticals.

Innovative radiotherapies (2)

• Rachel Delorme (Univ. Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3, 38000 Grenoble, France)

These lectures will cover an ntroduction to the physical and radiobiological characteristics of the different approaches and technological issues associated with their development. The approach in developing new radiotherapy (RT) approaches is to succeed in increasing the therapeutic window for different types of cancer, either by sparing healthy tissues, or by being more effective on the tumor tissue to be treated, ideally both at the same time. An introduction will be given presenting different developments in modern X-ray RT with successive generations of irradiation techniques improving the conformation of the dose to the tumor and optimized dose delivery for the patient's response. The limits of external RT will be discussed and a broad description of development strategies developed to overcome these limits will be given, in particular to see how we can play on the physical aspects of irradiation to induce a different biological response. We will emphasize the interest of using beams different from photons, such as light ions (H, C) used in hadrontherapy, which have the dual advantage of providing better irradiation ballistics and increased biological efficiency for radioresistant cancers. Other approaches also play on the temporal and spatial aspects of dose delivery, such as “FLASH” radiotherapy using a very high dose rate and “spatial fractionation” using very heterogeneous irradiation with micrometric beams, to induce better tolerance of healthy tissues to irradiation for the same tumor control. Finally, non-localized or metastatic cancers can benefit from combined approaches with the use of a pharmaceutical agent allowing molecular targeting of cancer cells, as is the case with internal radiotherapy or boron neutron capture (BNCT). Finally, we will briefly introduce the questions that these RT raises, whether in terms of understanding the induced radiobiological mechanisms or the technological developments that they require in terms of production, dosimetry or detection, these different aspects being the subject of specific courses in the following.

Imaging techniques (1)

• Laurent MENARD (IJCLab - Pôle Physique Santé)

Imagerie anatomique, fonctionnelle, moléculaire : modalités TEP, SPECT, IRM, ultrasons, tomographie, multimodalité, radiographie ionique

Poster session 1

Radiobiology (for physicists): experimental aspects 2

• Julie Costanzo (ICM Montpellier)

Aspects expérimentaux, méthodologiques, instrumentaux et phénoménologiques de la radiobiologie

Detectors: specific challenges for medical applications (1)

• Christian Finck (CNRS - IPHC)

Since the middle of the last century nuclear detectors have been used in medical application as well for diagnostic or treatment, especially in cancer patient course. Beside the conventional X-rays imaging for diagnostic, scintillators are used for single photon (SPECT: Single-Photon Emission Computed Tomography) or double photon (PET: Positron Emission Tomograpghy) 3D image reconstruction. In the last decade, liquid xenon detectors were developed for a 3-gamma image reconstruction. The used of charged particle to treat cancer tumor was already proposed end of the 40’. It is a modality that is now widely used to treat specific types of cancer (mostly neck and head, or pediatric cancers). The incident energy is provided to the particle by nuclear accelerators (cyclotron or synchrotron). The beam quality is assessed by dedicated sensors, based on thin solid detectors (e.g.: scintillator) or gaseous detectors (e.g.: drift chamber). Detectors are also used to assess quality of treatment planning system (TPS), as the reduction of TPS uncertainties is one of the major challenges in particle therapy. For example, the beam undergoes, beside energy losses, nuclear reactions, which have to be taken into account in the treatment planning system (TPS) before irradiation. Dedicated experiments were carried out to measure nuclear cross sections foreseen as input for the TPS. Furthermore, to limit uncertainties due to the computing of energy losses from X-rays imaging during TPS, a new idea raised up to use the same particle for diagnostic and for treatment. Thus, proton or carbon imaging [2] was developed in the last decade using solid detectors (e.g.: silicon or scintillator sensors). In the lectures, the different detectors will be presented in the context of medical application.

Geant4-DNA examples for radiobiology

• Hoang Tran (LP2iB)

Geant4-DNA is an extension of the Geant4 Monte Carlo toolkit designed for mechanistic studies of cellular radiobiological effects at the DNA scale. It simulates the physical, chemical, and biological stages of ionizing radiation, including electrons, protons, alpha particles, and heavier ions, for various applications. The applications of Geant4-DNA range from predicting radiotherapy outcomes to radiation protection and space applications. These lectures provide an overview of the progress achieved with physical, physicochemical, chemical, and biological geometry models integrated into Geant4-DNA. The latest developments are highlighted, including user-friendly applications such as 'molecularDNA' and 'dsbandrepair', which are based on these models. These applications allow for quantitative predictions of early DNA damage, such as single-strand breaks (SSBs), double-strand breaks (DSBs), and the complexity of clustered lesions across different levels of DNA structure, from the DNA base to the full genome of a human cell. The lectures will present sets of models, functionalities, and user examples in Geant4-DNA. These capabilities allow for the investigation of radiation quality across a range of ionizing radiations, covering a broad spectrum of radiotherapeutic modalities. This spectrum includes high-energy hadron beams, as well as low-energy gamma, beta, or alpha emitters used in brachytherapy sources and radiopharmaceuticals.

Imaging techniques (2)

• Laurent MENARD (IJCLab - Pôle Physique Santé)

Imagerie anatomique, fonctionnelle, moléculaire : modalités TEP, SPECT, IRM, ultrasons, tomographie, multimodalité, radiographie ionique

Accelerators (1)

• Marco Pullia (CNAO)

Accélérateurs pour la radiothérapie et l’hadronthérapie, systèmes de délivrance isocentriques, accélérateurs pour la BNCT et la production de radioisotopes, contraintes cliniques

Poster session 2

Innovative radioisotopes (1)

• Arnaud Guertin (CNRS/IN2P3)

Pour une imagerie et des traitements combinés (approche théranostique), vers une médecine personnalisée. Enjeux de production quantitative et qualitative

Detectors: specific challenges for medical applications (2)

• Christian Finck (CNRS - IPHC)

Since the middle of the last century nuclear detectors have been used in medical application as well for diagnostic or treatment, especially in cancer patient course. Beside the conventional X-rays imaging for diagnostic, scintillators are used for single photon (SPECT: Single-Photon Emission Computed Tomography) or double photon (PET: Positron Emission Tomograpghy) 3D image reconstruction. In the last decade, liquid xenon detectors were developed for a 3-gamma image reconstruction. The used of charged particle to treat cancer tumor was already proposed end of the 40’. It is a modality that is now widely used to treat specific types of cancer (mostly neck and head, or pediatric cancers). The incident energy is provided to the particle by nuclear accelerators (cyclotron or synchrotron). The beam quality is assessed by dedicated sensors, based on thin solid detectors (e.g.: scintillator) or gaseous detectors (e.g.: drift chamber). Detectors are also used to assess quality of treatment planning system (TPS), as the reduction of TPS uncertainties is one of the major challenges in particle therapy. For example, the beam undergoes, beside energy losses, nuclear reactions, which have to be taken into account in the treatment planning system (TPS) before irradiation. Dedicated experiments were carried out to measure nuclear cross sections foreseen as input for the TPS. Furthermore, to limit uncertainties due to the computing of energy losses from X-rays imaging during TPS, a new idea raised up to use the same particle for diagnostic and for treatment. Thus, proton or carbon imaging [2] was developed in the last decade using solid detectors (e.g.: silicon or scintillator sensors). In the lectures, the different detectors will be presented in the context of medical application.

Accelerators (2)

• Marco Pullia (CNAO)

Accélérateurs pour la radiothérapie et l’hadronthérapie, systèmes de délivrance isocentriques, accélérateurs pour la BNCT et la production de radioisotopes, contraintes cliniques

Simulation tools

• Marie Vanstalle (IPHC)
• Marc-Antoine Verdier (IJCLab - Université Paris Cité)

Plateforme GATE en imagerie et en radiothérapie (Travaux pratiques prolongeant le cours, sur un serveur déporté)

Innovative radioisotopes (2)

• Arnaud Guertin (CNRS/IN2P3)

Pour une imagerie et des traitements combinés (approche théranostique), vers une médecine personnalisée. Enjeux de production quantitative et qualitative

Dosimetry: determining the absorbed dose in photon and electron beams with ionization chambers

• Charlotte Robert (Hopital Villejuif)

Radiotherapy uses ionising radiation to damage the DNA of tumour cells. According to international recommendations (ICRU), the doses delivered during treatment must not deviate by -5%/+7% from the doses prescribed by the radiation oncologist in order to maximize local control and limit complications. To achieve this, it is necessary to describe the properties of the radiation beams precisely. The first part of the course (1 hour) will explain the methodology used by medical physicists to accurately assess the absolute doses generated by linear accelerators under reference conditions. The 2nd part of the course will describe the operating principles of the main relative dosimeters used to characterise longitudinal and transverse dose distributions and/or point doses. The limitations of these detectors for new irradiation strategies (ultra-high dose rate, mini-beams) will be discussed.

PET Image Reconstruction: from Convex Optimisation to Deep Learning (1)

• Florent Sureau (CEA Saclay)

Dosimetry: detectors for assessing dose distributions

• Charlotte Robert (Hopital Villejuif)

Radiotherapy uses ionising radiation to damage the DNA of tumour cells. According to international recommendations (ICRU), the doses delivered during treatment must not deviate by -5%/+7% from the doses prescribed by the radiation oncologist in order to maximize local control and limit complications. To achieve this, it is necessary to describe the properties of the radiation beams precisely. The first part of the course (1 hour) will explain the methodology used by medical physicists to accurately assess the absolute doses generated by linear accelerators under reference conditions. The 2nd part of the course will describe the operating principles of the main relative dosimeters used to characterise longitudinal and transverse dose distributions and/or point doses. The limitations of these detectors for new irradiation strategies (ultra-high dose rate, mini-beams) will be discussed.

Accelerators (3) : laser-plasma acceleration for medical applications

• Antoine Maitrallain (CENBG)
• Antoine Maitrallain (CNRS/LP2iB)

Electrons and light ions have been accelerated following the interaction of an intense laser pulse with a plasma for about 30 years. Nowadays, Laser Plasma Accelerators (LPA) are versatile sources capable of producing energetic electron and ion bunches with remarkable propreties. LPA benefited from the constantly increasing repetition rates of high intensity lasers that increased from a shot per hour to the Hz firing rate today and 100 Hz is foreseen within the next 5 years. Indeed LPA can be tuned to deliver particles with kinetic energies of up to several GeV for electrons and that reach 10 s of MeV for ions with charges approaching the μC level over accelerating distances of less than 20 cm or a few μm respectively. In the near future, they are poised to become complementary to conventional accelerators for specific purposes. Fundamental investigations are still necessary to understand the non linear processes at play in some of these acceleration mechanisms but the vast po- tential for usage led to the study of a number of applications in the past two decades. After briefly describing the most common acceleration processes and the properties of the obtained particle beams, the focus of this course will be the generation of medical radio isotopes from the multi-particles LPA sources [3] for internal radiotherapy and imaging. External radiotherapy using LPA bunches will also be discussed as well as phase contrast imaging that benefits from the unprecedented characteristics of these beams.

PET Image Reconstruction: from Convex Optimisation to Deep Learning (2)

• Florent Sureau (CEA Saclay)

TBD